MY172156A - Modulators of methyl modifying enzymes, compositions and uses thereof - Google Patents
Modulators of methyl modifying enzymes, compositions and uses thereofInfo
- Publication number
- MY172156A MY172156A MYPI2015001865A MYPI2015001865A MY172156A MY 172156 A MY172156 A MY 172156A MY PI2015001865 A MYPI2015001865 A MY PI2015001865A MY PI2015001865 A MYPI2015001865 A MY PI2015001865A MY 172156 A MY172156 A MY 172156A
- Authority
- MY
- Malaysia
- Prior art keywords
- compositions
- modulators
- modifying enzymes
- methyl modifying
- methyl
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010033040 Histones Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597695P | 2012-02-10 | 2012-02-10 | |
| US201261667821P | 2012-07-03 | 2012-07-03 | |
| PCT/US2013/025639 WO2013120104A2 (en) | 2012-02-10 | 2013-02-11 | Modulators of methyl modifying enzymes, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY172156A true MY172156A (en) | 2019-11-15 |
Family
ID=48948171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015001865A MY172156A (en) | 2012-02-10 | 2014-02-11 | Modulators of methyl modifying enzymes, compositions and uses thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US9085583B2 (enExample) |
| EP (1) | EP2812001B1 (enExample) |
| JP (2) | JP5989805B2 (enExample) |
| AR (1) | AR094755A1 (enExample) |
| AU (1) | AU2013216721B2 (enExample) |
| BR (1) | BR112015018508B1 (enExample) |
| CA (1) | CA2862289C (enExample) |
| CY (1) | CY1119060T1 (enExample) |
| DK (1) | DK2953941T3 (enExample) |
| EA (1) | EA029089B9 (enExample) |
| ES (1) | ES2632241T3 (enExample) |
| HR (1) | HRP20171030T1 (enExample) |
| LT (1) | LT2953941T (enExample) |
| MX (1) | MX363392B (enExample) |
| MY (1) | MY172156A (enExample) |
| NZ (1) | NZ628762A (enExample) |
| PT (1) | PT2953941T (enExample) |
| SM (1) | SMT201700340T1 (enExample) |
| UA (1) | UA117362C2 (enExample) |
| WO (1) | WO2013120104A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| NZ628762A (en) * | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| RU2018145311A (ru) | 2012-10-15 | 2019-02-18 | Эпизайм, Инк. | Способы лечения рака |
| MA38341B1 (fr) * | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| CN105473580A (zh) | 2013-07-10 | 2016-04-06 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | Zeste同源物增强子2抑制剂 |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| EP3033334A1 (en) * | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015078417A1 (zh) * | 2013-11-29 | 2015-06-04 | 四川好医生药业集团有限公司 | 吡咯并嘧啶化合物及其在制备降血糖药物中的用途 |
| WO2015200650A1 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
| US20170334891A1 (en) * | 2014-10-28 | 2017-11-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US20180037568A1 (en) * | 2015-02-13 | 2018-02-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
| WO2017018975A1 (en) | 2015-07-24 | 2017-02-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
| WO2017023671A1 (en) | 2015-08-03 | 2017-02-09 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitors and modulation of regulatory t-cell function |
| WO2017025493A1 (en) * | 2015-08-12 | 2017-02-16 | Bayer Pharma Aktiengesellschaft | Quinoline ezh2 inhibitors |
| CN108025191A (zh) | 2015-08-24 | 2018-05-11 | Epizyme股份有限公司 | 治疗癌症的方法 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| CN108699046A (zh) | 2015-10-06 | 2018-10-23 | Epizyme股份有限公司 | 用ezh2抑制剂治疗成神经管细胞瘤的方法 |
| JP2019500623A (ja) | 2015-11-05 | 2019-01-10 | エピザイム，インコーポレイティド | ヒストンｈ３メチル化ステータスをモニターするためのフローサイトメトリー |
| AU2017211331A1 (en) | 2016-01-29 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2017157825A1 (en) | 2016-03-15 | 2017-09-21 | F. Hoffmann-La Roche Ag | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| JP7208898B2 (ja) | 2016-12-02 | 2023-01-19 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| WO2018136596A1 (en) | 2017-01-20 | 2018-07-26 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2018231973A1 (en) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| WO2019014191A1 (en) | 2017-07-10 | 2019-01-17 | Constellation Pharmaceuticals, Inc. | GENE EXPRESSION INDUCED BY EZH2 INHIBITOR |
| EP3707136B1 (en) | 2017-11-09 | 2022-05-04 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| BR112020008325A2 (pt) | 2017-11-14 | 2020-10-20 | Pfizer Inc. | terapias de combinação com o inibidor de ezh2 |
| PL3716952T3 (pl) | 2017-11-29 | 2022-05-02 | Kalvista Pharmaceuticals Limited | Postacie dawkowania zawierające inhibitor kalikreiny osoczowej |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| CN111757734A (zh) | 2017-12-28 | 2020-10-09 | 星座制药公司 | 通过组合疗法的ezh2抑制剂的药代动力学增强 |
| WO2019152419A1 (en) | 2018-01-31 | 2019-08-08 | Mirati Therapeutics, Inc | Prc2 inhibitors |
| MX2020009530A (es) | 2018-03-14 | 2021-01-15 | Biogen Ma Inc | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. |
| PE20201448A1 (es) * | 2018-04-18 | 2020-12-10 | Constellation Pharmaceuticals Inc | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos |
| EP3823671B1 (en) | 2018-07-09 | 2024-02-07 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| TWI863926B (zh) | 2018-09-19 | 2024-12-01 | 美商百健Ｍａ公司 | O-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃醣苷酶抑制劑 |
| US20200131156A1 (en) * | 2018-10-30 | 2020-04-30 | H. Lundbeck A/S | ARYLSULFONYLPYROLECARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS |
| US12319679B2 (en) | 2018-12-05 | 2025-06-03 | Biogen Ma Inc. | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| WO2020139339A1 (en) | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Ezh2 and androgen receptor signaling inhibitors as tools for targeting prostate cancer |
| CN110357840B (zh) * | 2019-01-22 | 2022-04-12 | 石家庄和中科技有限公司 | 4-糠硫基戊酮-2的制备方法 |
| JP7504898B2 (ja) | 2019-02-04 | 2024-06-24 | バイオジェン・エムエイ・インコーポレイテッド | 二環式エーテルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
| JP7663503B2 (ja) | 2019-03-08 | 2025-04-16 | バイオジェン・エムエイ・インコーポレイテッド | アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
| EP3959214A1 (en) | 2019-04-22 | 2022-03-02 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as prc2 inhibitors |
| CA3142711A1 (en) | 2019-06-05 | 2020-12-10 | Mirati Therapeutics, Inc. | Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer |
| BR112022001154A2 (pt) * | 2019-07-24 | 2022-06-07 | Constellation Pharmaceuticals Inc | Terapias de inibição de ezh2 para o tratamento de cânceres |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| WO2021086966A1 (en) | 2019-10-29 | 2021-05-06 | Biogen Ma Inc. | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
| WO2022031701A1 (en) | 2020-08-03 | 2022-02-10 | Biogen Ma Inc. | Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor |
| WO2022150962A1 (en) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Protease inhibitors, preparation, and uses thereof |
| CN118026860A (zh) * | 2024-02-05 | 2024-05-14 | 福建福瑞明德药业有限公司 | 一种3-[1-(二甲基氨基)乙基]苯酚的制备方法 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| US5308854A (en) | 1990-06-18 | 1994-05-03 | Merck & Co., Inc. | Inhibitors of HIV reverse transcriptase |
| HUP9904335A3 (en) | 1996-07-22 | 2001-07-30 | Daiichi Asubio Pharma Co Ltd | Arylpiperidinol and arylpiperidine derivatives and drugs containing the same |
| NZ531928A (en) | 2001-09-04 | 2005-10-28 | Boehringer Ingelheim Pharma | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| MXPA03000145A (es) * | 2002-01-07 | 2003-07-15 | Pfizer | Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4. |
| AU2003220401A1 (en) | 2002-03-18 | 2003-10-08 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| TW200500341A (en) | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| AU2005211349A1 (en) | 2004-01-30 | 2005-08-18 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | N-benzyl-3,4-dihyroxypyridine-2-carboxamide and N-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as HIV integrase inhibitors |
| ZA200609259B (en) | 2004-04-30 | 2008-07-30 | Takeda Pharmaceutical | Heterocyclic amide compound and use thereof as an mmp-13 inhibitor |
| US7563589B2 (en) | 2004-06-01 | 2009-07-21 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
| WO2007011626A2 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2009503014A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患の治療におけるジヒドロプテリジノン |
| CN101326292A (zh) | 2005-12-08 | 2008-12-17 | 诺瓦提斯公司 | Fgfr3抑制物对基因转录的影响 |
| EP2913322A3 (en) | 2006-11-03 | 2015-11-11 | Korea Research Institute Of Chemical Technology | Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same |
| AU2008206168B2 (en) | 2007-01-19 | 2012-01-19 | The Regents Of The University Of Michigan | ADRB2 cancer markers |
| WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
| US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| WO2009015203A1 (en) | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| FR2922209B1 (fr) | 2007-10-12 | 2010-06-11 | Sanofi Aventis | 5,6-DIARYLES PYRIDINES SUBSTITUES EN POSITION 2 et 3, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE. |
| JP2011506333A (ja) | 2007-12-06 | 2011-03-03 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| UY31736A (es) | 2008-03-26 | 2009-11-10 | Takeda Pharmaceutical | Derivados sustituidos de pirazol y su uso |
| JP2011524894A (ja) | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| WO2010056564A1 (en) | 2008-11-13 | 2010-05-20 | Merck Sharp & Dohme Corp. | Quinolone neuropeptide s receptor antagonists |
| WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
| US8468343B2 (en) | 2010-01-13 | 2013-06-18 | Futurewei Technologies, Inc. | System and method for securing wireless transmissions |
| EP2556172A4 (en) | 2010-04-06 | 2013-10-30 | Caris Life Sciences Luxembourg Holdings | CIRCULATING BIOMARKERS FOR DISEASES |
| US8575203B2 (en) | 2010-04-21 | 2013-11-05 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| ES2528269T3 (es) * | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| JP5864546B2 (ja) * | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| AU2011291599B2 (en) | 2010-08-18 | 2015-09-10 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for disease |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012051492A2 (en) | 2010-10-14 | 2012-04-19 | University Of Georgia Research Foundation, Inc. | Compounds and methods for inhibiting hiv latency |
| US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5908493B2 (ja) * | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インドール |
| CN103492590A (zh) | 2011-02-22 | 2014-01-01 | 卡里斯生命科学卢森堡控股有限责任公司 | 循环生物标志物 |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| ES2624986T3 (es) | 2011-09-13 | 2017-07-18 | Glaxosmithkline Llc | Azaindazoles |
| JP2014534178A (ja) | 2011-09-30 | 2014-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 癌の処置方法 |
| WO2013067300A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| CA2854447A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of treatment |
| WO2013067302A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20130230511A1 (en) | 2012-02-03 | 2013-09-05 | Board Of Regents, The University Of Texas System | Biomarkers for response to tyrosine kinase pathway inhibitors in cancer |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AU2013232229B2 (en) | 2012-03-12 | 2017-11-23 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| LT2836491T (lt) | 2012-04-13 | 2017-03-27 | Epizyme, Inc. | Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma |
| SG10201608579UA (en) | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| JP6254169B2 (ja) * | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
| RU2018145311A (ru) | 2012-10-15 | 2019-02-18 | Эпизайм, Инк. | Способы лечения рака |
| JP6461802B2 (ja) * | 2012-10-15 | 2019-01-30 | エピザイム，インコーポレイティド | 置換ベンゼン化合物 |
| CN103794728A (zh) | 2012-10-30 | 2014-05-14 | 中国科学院长春光学精密机械与物理研究所 | 高导电性有机透明导电薄膜的制备方法 |
| NZ708563A (en) | 2012-11-01 | 2019-02-22 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014077784A1 (en) | 2012-11-19 | 2014-05-22 | Agency For Science, Technology And Research | Method of treating cancer |
| US20150292030A1 (en) | 2012-11-27 | 2015-10-15 | Board Of Regents, The University Of Texas System | Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer |
| US9895390B2 (en) | 2012-12-10 | 2018-02-20 | Children's Medical Center Corporation | Methods and assays for combination treatment of cancer |
| WO2014100080A1 (en) | 2012-12-19 | 2014-06-26 | Glaxosmithkline Llc | Combination |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| HK1214815A1 (zh) * | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| EP3022195A2 (en) * | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US9374093B2 (en) | 2014-01-10 | 2016-06-21 | Freescale Semiconductor, Inc. | Capacitively coupled input buffer |
| WO2015200650A1 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Substituted benzene and 6,5-fused bicyclic heteroaryl compounds |
-
2013
- 2013-02-11 NZ NZ628762A patent/NZ628762A/en unknown
- 2013-02-11 WO PCT/US2013/025639 patent/WO2013120104A2/en not_active Ceased
- 2013-02-11 CA CA2862289A patent/CA2862289C/en active Active
- 2013-02-11 JP JP2014556793A patent/JP5989805B2/ja active Active
- 2013-02-11 EP EP13746186.9A patent/EP2812001B1/en active Active
- 2013-02-11 AU AU2013216721A patent/AU2013216721B2/en active Active
- 2013-02-11 US US14/377,214 patent/US9085583B2/en active Active
-
2014
- 2014-02-11 MY MYPI2015001865A patent/MY172156A/en unknown
- 2014-02-11 ES ES14708987.4T patent/ES2632241T3/es active Active
- 2014-02-11 BR BR112015018508-8A patent/BR112015018508B1/pt active IP Right Grant
- 2014-02-11 HR HRP20171030TT patent/HRP20171030T1/hr unknown
- 2014-02-11 MX MX2015010377A patent/MX363392B/es unknown
- 2014-02-11 DK DK14708987.4T patent/DK2953941T3/en active
- 2014-02-11 AR ARP140100433A patent/AR094755A1/es active IP Right Grant
- 2014-02-11 SM SM20170340T patent/SMT201700340T1/it unknown
- 2014-02-11 PT PT147089874T patent/PT2953941T/pt unknown
- 2014-02-11 EA EA201591474A patent/EA029089B9/ru unknown
- 2014-02-11 UA UAA201508755A patent/UA117362C2/uk unknown
- 2014-02-11 US US14/766,632 patent/US20150376190A1/en not_active Abandoned
- 2014-02-11 LT LTEP14708987.4T patent/LT2953941T/lt unknown
- 2014-02-11 JP JP2015557190A patent/JP5989923B2/ja active Active
-
2015
- 2015-03-18 US US14/661,797 patent/US9371331B2/en active Active
- 2015-08-28 US US14/839,273 patent/US9469646B2/en not_active Ceased
-
2016
- 2016-05-16 US US15/155,749 patent/US9980952B2/en active Active
- 2016-09-06 US US15/257,275 patent/US10016405B2/en active Active
-
2017
- 2017-07-05 CY CY20171100718T patent/CY1119060T1/el unknown
-
2018
- 2018-01-24 US US15/878,663 patent/USRE47428E1/en active Active
- 2018-05-31 US US15/994,005 patent/US20190125737A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY172156A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| PH12015501720A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| WO2013075083A8 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| WO2013075084A8 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| WO2015023915A8 (en) | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof | |
| WO2012068589A3 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2015003874A (es) | Modulacion de ire1. | |
| PH12013500237A1 (en) | Pest control agent | |
| IN2014DN09346A (enExample) | ||
| PH12013500386A1 (en) | Pesticidal compositions | |
| PH12013500360B1 (en) | Pesticidal compositions | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
| MX2015008064A (es) | Composiciones pesticidas y procesos relacionados con ellas. | |
| IN2015DN03029A (enExample) | ||
| MX364069B (es) | Moduladores de la proteína activadora de 5-lipoxigenasa. | |
| PH12013501654A1 (en) | Pesticidal compositions and processes related thereto | |
| MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
| WO2014097318A3 (en) | Agents for eliminating tumour-initiating cells | |
| CA2875305C (en) | Fbxo3 inhibitors | |
| MX2016014179A (es) | Derivados quinazolindiona farcologicamente activos. | |
| MX2015006419A (es) | Tratamiento de la intolerancia al gluten y padecimientos relacionados. | |
| UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства | |
| UA72478U (ru) | Применение полентара как средства фригопротекторного действия | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| UA79866U (ru) | Применение 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с антидепрессивным действием |